Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tissue Transplantation01:24

Tissue Transplantation

1.1K
Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
1.1K
Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

534
A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
534
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

1.5K
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Making space and opportunities for talent to grow.

JHEP reports : innovation in hepatology·2026
Same author

Pre-liver transplant assessment of patients with acute-on-chronic liver failure: An international survey.

JHEP reports : innovation in hepatology·2026
Same author

Prospective comparison of viscoelastic coagulation monitor (VCM) and rotational thromboelastometry (ROTEM) in the assessment of cirrhosis coagulopathy.

Thrombosis research·2026
Same author

Letter to the Editor: Bacterial Infection, Platelet Dysfunction and Thromboinflammation in Decompensated Cirrhosis.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

Letter to the Editor: Liver transplantation in AH-ACLF-Which condition drives post-transplant outcomes?

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·2026
Same author

Physical frailty is the most important predictor of early mortality in hospitalized patients with decompensated cirrhosis.

Hepatology communications·2026

Related Experiment Video

Updated: Feb 19, 2026

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection
10:25

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection

Published on: February 19, 2019

12.2K

Hepatitis B and liver transplantation.

Alberto Ferrarese1, Alberto Zanetto1, Francesco P Russo2

  • 1Multivisceral Transplant Unit, Gastroenterology, Department of Surgery, Oncology and Gastroenterology, Padua University Hospital, Padua, Italy.

Minerva Gastroenterologica E Dietologica
|November 11, 2017
PubMed
Summary

Liver transplantation (LT) offers the best outcome for hepatitis B virus (HBV)-related liver disease. Combining hepatitis B immunoglobulin (HBIG) with nucleoside/nucleotide analogues (NUC) prevents HBV recurrence post-transplant.

More Related Videos

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

7.4K
Porcine Liver Transplantation Without Veno-Venous Bypass As an Extended Criteria Donor Model
12:49

Porcine Liver Transplantation Without Veno-Venous Bypass As an Extended Criteria Donor Model

Published on: August 17, 2022

3.2K

Related Experiment Videos

Last Updated: Feb 19, 2026

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection
10:25

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection

Published on: February 19, 2019

12.2K
Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

7.4K
Porcine Liver Transplantation Without Veno-Venous Bypass As an Extended Criteria Donor Model
12:49

Porcine Liver Transplantation Without Veno-Venous Bypass As an Extended Criteria Donor Model

Published on: August 17, 2022

3.2K

Area of Science:

  • Hepatology
  • Transplant Surgery
  • Virology

Background:

  • Liver transplantation (LT) is the primary treatment for end-stage liver disease caused by hepatitis B virus (HBV).
  • Outcomes have improved with nucleoside/nucleotide analogues (NUCs), with entecavir and tenofovir as current first-line options for HBV decompensated cirrhosis.
  • Hepatitis B immunoglobulin (HBIG) introduction significantly reduced HBV recurrence and improved survival post-LT.

Purpose of the Study:

  • To review current strategies for managing HBV in liver transplant recipients.
  • To highlight the efficacy of combined HBIG and NUC prophylaxis.
  • To discuss personalized approaches and the safe use of HBV-positive grafts.

Main Methods:

  • Literature review of HBV management in LT.
  • Analysis of prophylactic strategies against HBV recurrence.
  • Evaluation of donor selection criteria for HBV-positive grafts.

Main Results:

  • Combination therapy with HBIG and NUCs is the standard of care for preventing HBV recurrence.
  • Personalized therapeutic algorithms considering pre- and post-transplant factors are being developed.
  • Liver grafts from hepatitis B core antibody-positive and hepatitis B antigen-positive donors can be safely utilized in select patients.

Conclusions:

  • Effective prophylaxis against HBV recurrence post-LT is achievable with current therapies.
  • Personalized medicine and careful donor selection optimize outcomes in HBV-infected liver transplant recipients.
  • Continued research into risk stratification and management strategies is essential.